Table 1

Neutralization IC50s for 21 PG9-resistant HIV-1 Env pseudoviruses and their corresponding gain-of-function mutants

CladeVirusaIC50 (μg/ml)b
V1/V2 MAbsControl MAbsc
PG9PG16CH01CH04PGT141PGT145VRC01F10517bPGT1284E10
C3873>50>50>50>500.0110.0090.475>50>500.0066.43
3873-E171K0.0180.0040.1610.3850.0030.0040.071>50>500.0062.75
C6631>50>50>50>50>50>50>50>50>504.07>50
6631-E169K0.2250.0471.660.75912.3>50>50>50>504.52>50
BBG1168>50>50>50>50>50>500.203>50>50>501.84
BG1168-ins171K4.990.276>50>50>500.5170.670>50>50>505.15
BJRFL>50>50>50>50>508.770.029>50>500.016.16
JRFL-E168K0.009<0.0030.1220.0950.110.0170.023>50>500.0064.04
AGT251>505.2313.629.5>500.3163.03>50>50>5010.3
T251-T169K0.0560.0222.513.67>500.0592.85>50>50>507.01
T251-Cd0.2100.104>50>500.0090.0383.35>50>50>5016.8
C6471>50>50>50>50>50>50>50>50>50>50>50
6471-E169K/E171K0.0450.0121.321.320.0430.080>50>50>50>508.57
BCNE4>50>50>50>50>50>500.35217.918.10.5460.822
CNE4-N128T/T130D>50>50>50>50>50>500.1650.55415.62.020.17
CNE4-ins171K0.312>50>50>50>50>500.2660.2360.214>500.043
CNE4-C0.04915.936.5>50>50>500.3210.3380.198>500.135
CCNE30>50>50>50>50>50>500.979>50>500.194.70
CNE30-F164E>50>50>50>50>50>500.714>50>500.41713.4
CNE30-F164E/H169K2.370.648>50>50>50>500.686>50>500.2559.51
B7165>50>50>50>502.150.06326.6>50>500.0041.79
7165-E173Y0.6030.0451.072.450.1510.029>50>50>500.0043.21
7165-C0.0200.0080.2090.608>500.031>50>50>50<0.0031.75
A398>50>500.2660.463>50>500.144>50>50<0.0038.56
398-C0.0040.0030.0590.0950.1440.380.081>50>50<0.0030.329
C6322>50>50>50>500.0130.105>50>50>50>5011.4
6322-C0.0190.0080.6961.14<0.003<0.003>50>50>50>507.10
D6405>50>50>50>50>50>501.53>50>503.869.10
6405-N166R>50>50>50>501.27>501.39>50>502.824.17
6405-C0.2450.1952.056.390.0040.1170.815>50>503.641.34
AECNE56>50>50>50>50>502.250.186>50>507.360.960
CNE56-C0.1650.0332.792.930.1280.8070.341>50>502.030.219
A0439>50>50>50>503.912.000.170>50>502.576.70
0439-C4.19>50>50>501.542.760.116>50>502.582.50
DA03349M1>50>50>50>50>502.712.83>50>500.014.60
A03349M1-C1.180.181>50>500.9370.0590.63710.4>500.0121.27
BQH0515>50>50>50>50>50>500.11>50>50>503.07
QH0515-ins171K>50>50>50>50>50>500.769>50>50>503.59
QH0515-C4.58>50>50>50>50>501.19>50>50>501.65
AQH209>50>50>50>50>500.0150.017>50>50>505.27
QH209-C0.390.124>50>50>50>500.025>50>50>504.81
BRHPA>500.816>5034.40.0640.0440.035>50>500.0105.66
RHPA-C0.6030.1017.7838.5>502.480.031>50>500.0085.03
GX2088>50>50>50>50>50>50>50>50>50>50>50
X2088-C0.110.694>50>50>50>50>50>50>50>50>50
CZM135>50>50>50>50>50>500.237>50>503.920.136
ZM135-C0.0990.03>50>500.0040.1481.19>50>505.680.746
CZM651>50>50>50>50>507.560.558>50>500.1010.462
ZM651-C22.5>50>50>502.938.221.3>50>50>501.38
  • a Strains marked with C have the CAP45 strand C swap as described in the text. Full names of strains are provided in Table S1 in the supplemental material.

  • b A value of >50 indicates no neutralization at 50 μg/ml. All other values are in bold. IC80s are reported in Table S1.

  • c Control MAb epitopes: VRC01 and F105, CD4 binding site; 17b, CD4 induced; PGT128, glycan/loop; 4E10, membrane-proximal region.